True. Immunohistochemistry is a cornerstone technique in the diagnosis and subclassification of lymphomas. Lymphomas are cancers of lymphocytes (B-cells, T-cells, or NK-cells), and their accurate classification is essential for prognosis and treatment. IHC uses panels of antibodies against lineage-specific markers to determine the cell of origin. For example: 1) **B-cell markers**: CD20, CD79a, PAX5. 2) **T-cell markers**: CD3, CD5, CD7. 3) **Other markers**: CD30 (for classical Hodgkin lymphoma and anaplastic large cell lymphoma), CD15 (Reed-Sternberg cells), and Ki-67 (proliferation index). By assessing the pattern and combination of marker expression on the neoplastic cells, a pathologist can distinguish between diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and many others. This precise classification, heavily reliant on IHC, directly guides therapeutic choices, such as the use of anti-CD20 therapy (Rituximab) for B-cell lymphomas.

Break down complex topics into smaller, manageable chunks for easier recall.

Zambia

• Joseph Soko – 101 pts

• Visual Pathway Lesions
• Positive and Negative Symptoms
• Hallucinations and Delusions
• Antipsychotic Medications
• Emergency: Environmental Emergencies